Quotient Limited to Publish Quarterly Investor Presentation

Rhea-AI Summary

Quotient Limited (NASDAQ: QTNT) published its investor presentation related to the fiscal quarter ending June 30, 2020. The presentation can be accessed on the company's investor relations webpage. Quotient, a diagnostics company with over 30 years in transfusion diagnostics, develops innovative solutions like the MosaiQ technology, which automates testing processes. Their COVID-19 Antibody Microarray, launched in April 2020, is CE marked and distributed in Europe, including the UK and Switzerland.

Positive

• Introduction of the MosaiQ COVID-19 Antibody Microarray, which is CE marked and available for distribution in Europe.
• MosaiQ technology offers a fully automated, consolidated testing platform that enhances efficiency and workflow in laboratories.

Negative

• None.

JERSEY, Channel Islands, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today published the latest investor presentation associated with the earnings call for fiscal quarter ended June 30, 2020.

A copy of the Company’s investor presentation will be available online on the investor relations page of the Company's corporate website at www.quotientbd.com.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and available for distribution in Europe including Switzerland, and the UK. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various jurisdictions.

Contact: Peter Buhler, Chief Financial Officer, peter.buhler@quotientbd.com; +41 22 545 52 26

 

FAQ

What is the latest investor presentation published by Quotient Limited?

Quotient Limited published its latest investor presentation associated with the earnings call for the fiscal quarter ending June 30, 2020.

What is the significance of the MosaiQ technology for Quotient Limited?

MosaiQ technology is a revolutionary fully automated, consolidated testing platform, improving efficiency and clinical practices in diagnostics.

Is the MosaiQ COVID-19 Antibody Microarray available for distribution?

Yes, the MosaiQ COVID-19 Antibody Microarray is CE marked and currently available for distribution in Europe, including Switzerland and the UK.

Where can I access Quotient Limited's investor presentation?

The investor presentation is available on Quotient Limited's investor relations page on their corporate website.